Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world sintilimab + bevacizumab + chemotherapy in EGFR-mutant NSCLC after EGFR-TKI failure
ChiCTR2500102604Phase 4Recruiting
- Sponsor
- Zhengzhou Third People's Hospital
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of sintilimab in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Zhengzhou Third People's Hospital. Primary endpoint: Objective response rate. Started May 2025; status: recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500102604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102604.